In 70 patients with LPDs who underwent APBSCT, the median infused CD34+ cells dose was 3.6 x [10.sup.6]/ kg (range 0.7-15.9).
There are many studies evaluating the factors affecting neutrophil and platelet engraftment after APBSCT. Most studies found that only infused CD34+ dosage correlated with faster neutrophil and platelet engraftment.
Our result was in agreement with another study which showed that the infusion of CD34+ cells > 7.0 x 106/kg had significant faster platelet engraftment time among patients with LPDs who underwent APBSCT. (11) The significant association of infused CD34+ dosage and platelet engraftment rather than neutrophil engraftment does support that the quality of stem cells function is better reflected by megakaryopoiesis rather than granulopoiesis.
Many transplant centers in European countries decide those patients who are less than 65 years old and have no comorbidities are primarily eligible candidates for APBSCT. (25) A majority of studies showed that patient's age was not associated with neither neutrophil nor platelet engraftment.
However, a few studies are suggesting that ideal body weight correlates better with engraftment after APBSCT than actual body weight.
However, there are no other studies related to APBSCT that support our finding.
Additionally, PD-1 is related to tumor immunosuppression, but PD-1 levels in MM patients that underwent autologous peripheral blood stem cell transplantation (APBSCT) haven't been reported.
MM patients that did and did not undergo APBSCT were included in the study.
All patients received first-line therapies and 11 patients underwent APBSCT. Blood was collected 40-110 d following transplantation.
In all, 11 of the patients underwent APBSCT. The clinical and histological features of the patients that did [APBSCT (+)] and did not [APBSCT (-)] undergo APBSCT are shown in Tables 1 and 2, respectively.
Clinical and histological features of the APBSCT (+) cases (n = 1) Gender Female 5 45.5% Male 6 54.5% Kappa (K) 5 45.5% Light Chain-Type Lamda (L) 5 45.5% NA 1 4.0% IgG 7 63.6% Ig Heavy Chain-Type IgA 2 18.2% NA 2 18.2% Stage 1 2 18.2% ISS Stage 2 5 45.5% Stage 3 2 18.2% NA 1 9.1% IA 1 9.1% IIA 3 27.3% Dude-Salmon Stage IIIA 3 27.3% IIIB 3 27.3% NA 2 9.1% Diffuse 5 45.5% Bone Marrow Biopsy Nodulary 5 45.5% Diffuse and Nodulary 1 9.1% VAD 6 54.5% Therapy CYP + DEX 4 36.4% NA 1 9.1% CR 1 9.1% PR 6 54.5% Therapy Response SD 2 18.2% Refractory 1 9.1% NA 1 9.1% Table 2.
CD4+CD25+FOXP3+ Treg levels ranged between 0% and 1 PM in all the cases, between 0.07% and 9% in the APBSCT (+) cases, and between 0% and 11% in the APBSCT (-) cases.